Carlyle’s Abingworth will help fund Teva’s Phase 3 asthma rescue inhaler

Abing­worth will pro­vide up to $150 mil­lion to help fund Te­va Phar­ma­ceu­ti­cals’ de­vel­op­ment of an asth­ma res­cue in­haler, the com­pa­nies said Mon­day morn­ing.

The as­set, known as ICS-SA­BA/TEV-’248, en­tered Phase 3 test­ing last fall and will have re­sults in the sec­ond half of 2026, ac­cord­ing to a Te­va pre­sen­ta­tion from Jan­u­ary.

The in­haler could work for adults and chil­dren, Te­va has said. It com­bines the “two most wide­ly used mol­e­cules,” which are flu­ti­ca­s­one pro­pi­onate and al­buterol sul­fate. The Is­rael-based phar­ma in Jan­u­ary tout­ed a $2.5 bil­lion po­ten­tial mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.